Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trails. In the future, immunotherapy and gene therapy may be of benefit but these are still many years from the clinical arena. We believe that current evidence suggests that patients with Dukes B and C colorectal cancer should be entered into trials of adjuvant therapy. This evidence is reviewed below among with estimates of the impact that adjuvant therapy would have on the outcome from this disease in Northern Ireland.
Wilson
R H
RH
Northern Ireland Centre for Clinical Oncology, Belvoir Park Hospital, Belfast.
Houston
R F
RF
Moorehead
R J
RJ
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D009660:Northern Ireland; D018714:Radiotherapy, Adjuvant
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil